Germany Diagnostic Biomarker Market Size, Share and Forecast 2019-2025Posted by pooja makkhar on February 20th, 2020 German diagnostic biomarker market is estimated to grow significantly at a CAGR of over 12% during the forecast period. It is due to the increasing geriatric population, the presence of highly specialized urologists for cancer treatment and bit low-cost treatment as compared to UK, which is attracting medical tourism in the country. In addition, Germany has a well-developed healthcare system and favorable government policies which are driving the market in the region. The German diagnostic biomarker market is segmented on the basis of diagnostic technique and application. On the basis of the diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. Further, on the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. A large number of researches are going on finding a diagnostic biomarker for various types of cancer so that early detection can be done. Request a Free Sample of our Report on @ https://www.omrglobal.com/request-sample/germany-diagnostic-biomarker-market Some of the major players in the Germany diagnostic biomarker market include Abbott Laboratories, Inc., F. Hoffmann-La Roche Ltd., Evotec AG, Becton Dickinson and Co., SphingoTec GmbH, InfanDx AG, Novartis AG, and others. These companies are adopting various strategies such as partnership and collaboration and product launch, in order to sustain in the competitive market. In addition, the players are involved in the R&D activities and filing patents for the same. For instance, in January 2020, InfanDx AG has been granted the US Patent 141013 US, titled „Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy”. The US Patent and Trademark Office approved the comprehensive patent, which covers the diagnosis of neonatal encephalopathy using biomarkers, at the end of December 2019. This is the second US patent for the HypoxE-test, following the patent for the diagnosis of perinatal asphyxia. In the EU, InfanDx had already been awarded patent protection for both indications. A full Report of Germany Diagnostic Biomarker Market is available at https://www.omrglobal.com/industry-reports/germany-diagnostic-biomarker-market Germany Diagnostic Biomarker Market Segmentation By Diagnostic Technique
By Application
Company Profiles
About us: Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 780-304-0404 Like it? Share it! More by this author |